Guo Xiao-Ru, Zhang Xiao-Guang, Wang Gang-Sheng, Wang Jia, Liu Xiao-Jun, Deng Jie-Hua
Department of Infectious Diseases, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Department of Dermatovenereology, Clinical Research Center for Dermatovenereology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Chin J Integr Med. 2025 Jul;31(7):644-648. doi: 10.1007/s11655-023-3754-5. Epub 2024 Apr 27.
To investigate the therapeutic efficacy of cinnamaldehyde (CA) on systemic Candida albicans infection in mice and to provide supportive data for the development of novel antifungal drugs.
Ninety BALB/c mice were randomly divided into 3 groups according to a random number table: CA treatment group, fluconazole (positive control) group, and Tween saline (negative control) group, with 30 mice in each group. Initially, all groups of mice received consecutive intraperitoneal injections of cyclophosphamide at 200 mg/kg for 2 days, followed by intraperitoneal injection of 0.25 mL C. albicans fungal suspension (concentration of 1.0 × 10 CFU/mL) on the 4th day, to establish an immunosuppressed systemic Candida albicans infection animal model. Subsequently, the mice were orally administered CA, fluconazole and Tween saline, at 240, 240 mg/kg and 0.25 mL/kg respectively for 14 days. After a 48-h discontinuation of treatment, the liver, small intestine, and kidney tissues of mice were collected for fungal direct microscopic examination, culture, and histopathological examination. Additionally, renal tissues from each group of mice were collected for (1,3)- β -D-glucan detection. The survival status of mice in all groups was monitored for 14 days of drug administration.
The CA group exhibited a fungal clearance rate of C. albicans above 86.7% (26/30), significantly higher than the fluconazole group (60.0%, 18/30, P<0.01) and the Tween saline group (30.0%, 9/30, P<0.01). Furthermore, histopathological examination in the CA group revealed the disappearance of inflammatory cells and near-normal restoration of tissue structure. The (1,3)-β-D-glucan detection value in the CA group (860.55 ± 126.73 pg/mL) was significantly lower than that in the fluconazole group (1985.13 ± 203.56 pg/mL, P<0.01) and the Tween saline group (5910.20 ± 320.56 pg/mL, P<0.01). The mouse survival rate reached 90.0% (27/30), higher than the fluconazole group (60.0%, 18/30) and the Tween saline group (30.0%, 9/30), with a significant difference between the two groups (both P<0.01).
CA treatment exhibited significant therapeutic efficacy in mice with systemic C. albicans infection. Therefore, CA holds potential as a novel antifungal agent for targeted treatment of C. albicans infection.
研究肉桂醛(CA)对小鼠系统性白色念珠菌感染的治疗效果,为新型抗真菌药物的研发提供支持数据。
90只BALB/c小鼠按随机数字表随机分为3组:CA治疗组、氟康唑(阳性对照)组和吐温生理盐水(阴性对照)组,每组30只。最初,所有组小鼠连续2天腹腔注射200mg/kg环磷酰胺,第4天腹腔注射0.25mL白色念珠菌真菌悬液(浓度为1.0×10CFU/mL),以建立免疫抑制的系统性白色念珠菌感染动物模型。随后,小鼠分别口服CA、氟康唑和吐温生理盐水,剂量分别为240、240mg/kg和0.25mL/kg,持续14天。停药48小时后,收集小鼠肝脏、小肠和肾脏组织进行真菌直接镜检、培养及组织病理学检查。此外,收集每组小鼠的肾组织进行(1,3)-β-D-葡聚糖检测。在给药的14天内监测所有组小鼠的生存状况。
CA组白色念珠菌的真菌清除率高于86.7%(26/30),显著高于氟康唑组(60.0%,18/30,P<0.01)和吐温生理盐水组(30.0%,9/30,P<0.01)。此外,CA组的组织病理学检查显示炎症细胞消失,组织结构近乎正常恢复。CA组的(1,3)-β-D-葡聚糖检测值(860.55±126.73pg/mL)显著低于氟康唑组(1985.13±203.56pg/mL,P<0.01)和吐温生理盐水组(5910.20±320.56pg/mL,P<0.01)。小鼠存活率达到90.0%(27/30),高于氟康唑组(60.0%,18/30)和吐温生理盐水组(30.0%,9/30),两组间差异有统计学意义(均P<0.01)。
CA治疗对系统性白色念珠菌感染的小鼠具有显著的治疗效果。因此,CA有潜力作为一种新型抗真菌剂用于靶向治疗白色念珠菌感染。